Abstract | PURPOSE: METHODS: This single-center, prospective, double-masked, randomized clinical trial consisted of 81 patients who were scheduled for cataract surgery. Patients were randomized to receive hypromellose/ dextran 70 as a placebo (n=44) or ketorolac tromethamine 0.4% (n=37) as an adjuvant therapy. These eye drops were administered 4 times daily (QID) for 3 days before surgery and 5 weeks postoperatively. All patients received prednisolone acetate 1% QID during the same period as basal/standard anti-inflammatory therapy. The primary outcome was the incidence of angiographic CME 5 weeks after surgery. The secondary outcomes were mean change in best-corrected visual acuity (BCVA) [Early Treatment Diabetic Retinopathy study (ETDRS)], clinical CME incidence, intraocular pressure, and retinal thickness measured using optical coherence tomography (OCT). RESULTS: In the placebo group, 2/44 (4.5%) patients and in the ketorolac group, 2/37 (5.4%) patients presented with angiographic CME (P=0.624). The mean change in postoperative BCVA was 32±15 letters in the placebo group and 26±16 letters in the ketorolac group (P=0.07). There were no statistically significant between-group differences in the mean central subfield thickness (P=0.679), minimal central thickness (P=0.352), or central macular volume (P=0.729). CONCLUSION: There was no difference between ketorolac tromethamine and a placebo with regard to BCVA results or prevention of CME after uncomplicated cataract surgery.
|
Authors | Flavia G Ticly, Rodrigo P C Lira, Fernando R Zanetti, Maria Cecília Machado, Gustavo B Rodrigues, Carlos Eduardo L Arieta |
Journal | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
(J Ocul Pharmacol Ther)
Vol. 30
Issue 6
Pg. 495-501
(Aug 2014)
ISSN: 1557-7732 [Electronic] United States |
PMID | 24735005
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Ophthalmic Solutions
- Ketorolac Tromethamine
- prednisolone acetate
- Prednisolone
|
Topics |
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, therapeutic use)
- Cataract Extraction
(methods)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Ketorolac Tromethamine
(administration & dosage, therapeutic use)
- Macular Edema
(etiology, prevention & control)
- Male
- Middle Aged
- Ophthalmic Solutions
- Prednisolone
(analogs & derivatives, therapeutic use)
- Prospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
(drug effects)
|